Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists

Journal of Medicinal Chemistry

Volumn 56, Issue 10, 2013, Pages 3852-3865

  Mistry, Shailesh N ^a   Baker, Jillian G ^a   Fischer, Peter M ^a   Hill, Stephen J ^a   Gardiner, Sheila M ^a   Kellam, Barrie ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 AMINOETHYL) 3 (4 BENZYLOXY)PHENYLUREA; 1 (2 AMINOETHYL) 3 (4 HYDROXY)PHENYLUREA; 1 (2 CYANOPHENOXY) 3 [2 (3 PHENYLUREIDO)ETHYLAMINO] 2 PROPANOL; 1 (BENZYLOXY) 4 [2 (CYCLOPENTYLOXY)ETHOXY]BENZENE; 1 [2 [3 [2 CYANO 4 [2 (CYCLOPROPYLMETHOXY)ETHOXY]PHENOXY] 2 HYDROXYPROPYLAMINO]ETHYL] 3 (4 HYDROXYPHENYL)UREA; 1 [2 [3 [4 [2 (CYCLOPROPYLMETHOXY)ETHOXY]PHENOXY] 2 HYDROXYPROPYLAMINO]ETHYL] 3 (4 HYDROXYPHENYL)UREA HYDROFORMATE; 2 [4 [2 (CYCLOPENTYLOXY)ETHOXY]PHENOXYMETHYL]OXIRANE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARBANILAMIDE; ISOPRENALINE; LK 204545; NITRILE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; SUBSTITUTION REACTION;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DRUG DESIGN; HEART RATE; HEMODYNAMICS; HUMANS; INDICATORS AND REAGENTS; LIGANDS; MALE; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878047219     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400348g     Document Type: Article

References (52)

1. Louis, S. N. S.; Nero, T. L.; Iakovidis, D.; Jackman, G. P.; Louis, W. J. LK 204-545, a highly selective β1-adrenoceptor antagonist at human β-adrenoceptors Eur. J. Pharmacol. 1999, 367, 431-435
2. Segal, M. S.; Beakey, J. F. The use of isuprel for the management of bronchial asthma Bull. New Engl. Med. Cent. 1947, 9, 62-67
3. Lowell, F. C.; Curry, J. J.; Schiller, I. W. A clinical and experimental study of isuprel in spontaneous and induced asthma N. Engl. J. Med. 1948, 239, 45-51
4. Black, J. W.; Stephenson, J. S. Pharmacology of a new adrenergic β-receptor-blocking compound (Nethalide) Lancet 1962, 2, 311-314
5. Black, J. W.; Duncan, W. A.; Shanks, R. G. Comparison of some properties of pronethalol and propranolol Br. J. Pharmacol. Chemother. 1965, 25, 577-591
6. Black, J. A life in new drug research Br. J. Clin. Pharmacol. 2010, 70, 442-451
7. Pedersen, T. R. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction N. Engl. J. Med. 1985, 313, 1055-1058
8. Cuculi, F.; Radovanovic, D.; Pedrazzini, G.; Regli, M.; Urban, P.; Stauffer, J. C.; Erne, P. AMIS Plus Investigators: Is pretreatment with B-blockers beneficial in patients with acute coronary syndrome? Cardiology 2010, 115, 91-97
9. Waagstein, F.; Hjalmarson, A.; Varnauskas, E.; Wallentin, I. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy Br. Heart J. 1975, 37, 1022-1036
10. Swedberg, K.; Hjalmarson, A.; Waagstein, F.; Wallentin, I. Prolongation of survival in congestive cardiomyopathy by β-receptor blockade Lancet 1979, 1, 1374-1376
11. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353, 9-13.
12. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet 1999, 353, 2001-2007.
13. Packer, M.; Fowler, M. B.; Roecker, E. B.; Coats, A. J. S.; Katus, H. A.; Krum, H.; Mohacsi, P.; Rouleau, J. L.; Tendera, M.; Staiger, C.; Holcslaw, T. L.; Amann-Zalan, I.; DeMets, D. L. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study Circulation 2002, 106, 2194-2199
14. Wild, D. M.; Kukin, M. β-Blockers to prevent symptomatic heart failure in patients with stage A and B heart failure Curr. Heart Fail. Rep. 2007, 4, 99-102
15. Baker, J. G.; Hill, S. J.; Summers, R. J. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling Trends Pharmacol. Sci. 2011, 32, 227-234
16. Patel, M.; Thomson, N. C. (R)-Salbutamol in the treatment of asthma and chronic obstructive airways disease Expert Opin. Pharmacother. 2011, 12, 1133-1141
17. 2-adrenergic receptors Cardiovasc. Drugs Ther. 1999, 13, 123-126
18. 3-adrenoceptors J. Cardiovasc. Pharm. 2000, 36, 466-471
19. Hoffmann, C.; Leitz, M. R.; Oberdorf-Maass, S.; Lohse, M. J.; Klotz, K. N. Comparative pharmacology of human β-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells N. S. Arch. Pharmacol. 2004, 369, 151-159
20. 3 adrenoceptors Br. J. Pharmacol. 2005, 144, 317-322
21. 3-adrenoceptors Br. J. Pharmacol. 2010, 160, 1048-1061
22. 1-adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships J. Pharmacol. Exp. Ther. 1980, 213, 406-413
23. Berthold, R.; Louis, W. J. 3-Aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them. Patent 4,661,513, 1987.
24. Talukdar, S.; Hsu, J.-L.; Chou, T.-C.; Fang, J.-M. Direct transformation of aldehydes to nitriles using iodine in ammonia water Tetrahedron Lett. 2001, 42, 1103-1105
25. Chen, S.-W.; Kim, J. H.; Song, C. E.; Lee, S.-G. Self-supported oligomeric Grubbs/Hoveyda-type Ru-carbene complexes for ring-closing metathesis Org. Lett. 2007, 9, 3845-3848
26. Nowak, I.; Robins, M. J. Synthesis of 3′-deoxynucleosides with 2-oxabicyclo[3.1.0]hexane sugar moieties: addition of difluorocarbene to a 3′,4′-unsaturated uridine derivative and 1,2-dihydrofurans derived from d-and l -xylose1 J. Org. Chem. 2007, 72, 3319-3325
27. Okimoto, M.; Chiba, T. Electrochemical transformations of aldehydes into methyl carboxylates and nitriles J. Org. Chem. 1988, 53, 218-219
28. McBriar, M. D.; Guzik, H.; Shapiro, S.; Paruchova, J.; Xu, R.; Palani, A.; Clader, J. W.; Cox, K.; Greenlee, W. J.; Hawes, B. E.; Kowalski, T. J.; O'Neill, K.; Spar, B. D.; Weig, B.; Weston, D. J.; Farley, C.; Cook, J. Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicyclo[3.1.0]hexyl ureas J. Med. Chem. 2006, 49, 2294-2310
29. Brimble, M. A.; Duncalf, L. J.; Phythian, S. J. Synthesis of the monomeric unit of γ-actinorhodin J. Chem. Soc., Perkin Trans. 1 1997, 1399-1404
30. Hoefle, M. L.; Hastings, S. G.; Meyer, R. F.; Corey, R. M.; Holmes, A.; Stratton, C. D. Cardioselective β-adrenergic blocking agents. 1. 1-((3,4-Dimethoxyphenethyl)amino)-3-aryloxy-2-propanols J. Med. Chem. 1975, 18, 148-152
31. Crowther, A. F.; Gilman, D. J.; McLoughlin, B. J.; Smith, L. H.; Turner, R. W.; Wood, T. M. β-Adrenergic blocking agents V. 1-Amino-3-(substituted phenoxy)-2-propanols J. Med. Chem. 1969, 12, 638-642
32. Smith, L. H. β-Adrenergic blocking agents 13. (3-Amino-2- hydroxypropoxy)benzamides J. Med. Chem. 1976, 19, 1119-1123
33. Smith, L. H. β-Adrenergic blocking agents 15. 1-Substituted ureidophenoxy-3-amino-2-propanols J. Med. Chem. 1977, 20, 705-708
34. Smith, L. H. β-Adrenergic blocking agents. 16. 1-(Acylaminomethyl-, ureidomethyl-, and ureidoethylphenoxy)-3-amino-2-propanols J. Med. Chem. 1977, 20, 1254-1258
35. Large, M. S.; Smith, L. H. β-Adrenergic blocking agents. 23. 1-[Substituted-amido)phenoxy]-3-[[(substituted-amido)alkyl]amino] propan-2-ols J. Med. Chem. 1983, 26, 352-357
36. 2-adrenoceptor antagonist activity of a series of para-substituted N -isopropylphenoxypropanolamines Eur. J. Med. Chem. 1999, 34, 919-937
37. 4 Synth. Commun. 1999, 29, 1257-1261
38. 1-Selective adrenoceptor antagonists. 2. 4-Ether-linked phenoxypropanolamines J. Med. Chem. 1983, 26, 1570-1576
39. Jensen, K. B.; Braxmeier, T. M.; Demarcus, M.; Frey, J. G.; Kilburn, J. D. Synthesis of guanidinium-derived receptor libraries and screening for selective peptide receptors in water Chem.-Eur. J. 2002, 8, 1300-1309
40. Englund, E. A.; Gopi, H. N.; Appella, D. H. An efficient synthesis of a probe for protein function: 2,3-diaminopropionic acid with orthogonal protecting groups Org. Lett. 2004, 6, 213-215
41. Lelais, G.; Micuch, P.; Josien-Lefebvre, D.; Rossi, F.; Seebach, D. Preparation of protected β2- and β3-homocysteine, β2- and β3-homohistidine, and β2-homoserine for solid-phase syntheses Helv. Chim. Acta 2004, 87, 3131-3159
42. 1-adrenoceptor J. Pharmacol. Exp. Ther. 2005, 313, 1163-1171
43. Stephenson, R. P. A modification of receptor theory Br. J. Pharmacol. Chemother. 1956, 11, 379-393
44. Baker, J. G.; Kemp, P.; March, J.; Fretwell, L.; Hill, S. J.; Gardiner, S. M. Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses FASEB J. 2011, 25, 4486-4497
45. Arch, J. R. S. Do low-affinity states of β-adrenoceptors have roles in physiology and medicine? Br. J. Pharmacol. 2004, 143, 517-518
46. 1-adrenoceptor Mol. Pharmacol. 2003, 63, 1312-1321
47. 1-adrenergic receptor Am. J. Physiol. Endocrinol. Metab. 2001, 280, E199-E202
48. 1-adrenoceptor and its relevance to cardiovascular pharmacology Pharmacol. Ther. 2008, 118, 303-336
49. 3-adrenoceptor Mol. Pharmacol. 2005, 68, 1645-1655
50. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 2012, 344, 1659-1667.
51. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 1990, 336, 1-6.
52. Donaldson, J.; Brown, A. M.; Hill, S. J. Influence of rolipram on the cyclic-3′,5′-adenosine monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex Biochem. Pharmacol. 1988, 37, 715-723